Contract covers the production of phase 1 clinical material for ET-101, a novel cancer therapeutic that targets cancer stem cells
Lonza will manufacture ET-101 at its mammalian development and manufacturing facility in Slough, UK
Basel (Switzerland), California (USA) 29 February 2012 – Lonza and Eclipse announced today an agreement for the production of Eclipse’s novel cancer therapeutic antibody, ET-101, using Light Path™ Development Services. ET-101 is under investigation for the inhibition of the growth of cancer stem cells. Under the agreement, Lonza will produce phase 1 clinical material at its development and manufacturing facility in Slough, UK.
Dr. Christopher Reyes, CSO of Eclipse Therapeutics said, "Lonza’s best-in-class antibody manufacturing capabilities will greatly support our development strategy to deliver the highest quality and most effective therapeutics targeting cancer stem cells. Moving into cell line development and subsequent manufacturing represents an important milestone for Eclipse.”
Cancer stem cells are a small subset of cells within a tumor that are thought to play a critical role in tumor initiation, recurrence and metastasis. ET-101 is a novel therapeutic antibody designed to target these cancer stem cells. Eliminating cancer stem cells, in conjunction with other therapies that address the tumor bulk, represents a new cancer treatment paradigm that could offer a distinct advantage over existing strategies and a solution for chemoresistance.
“Lonza is excited that Eclipse has chosen us to support this innovative field of novel cancer therapeutics”, said Dr. Stephan Kutzer, COO Lonza Custom Manufacturing. “We are pleased to offer development services specifically designed to support emerging companies during their early clinical milestones.”
Eclipse Therapeutics, Inc. (“Eclipse”) is a private biotechnology company dedicated to the discovery and development of therapeutics that target cancer stem cells and other forms of innovative cancer treatment. Cancer stem cells are a subset of cells within a tumor thought to play a critical role in tumor initiation, recurrence and metastasis. They are also implicated in resistance to current standard of care cancer treatments. Eclipse is leveraging its deep expertise in cancer stem cell biology and therapeutic antibodies to develop novel therapeutics that address unmet needs in cancer patient care. For more information, please visit http://www.eclipsetherapeutics.com.